Literature DB >> 2112221

Atherosclerosis: the importance of HDL cholesterol and prostacyclin: a role for niacin therapy.

M H Luria1.   

Abstract

Niacin reduces the incidence of non-fatal myocardial way infarction, confers a significant long-term survival benefit after recovery from myocardial infarction, and has had many years of study and usage by the medical community. Recent evidence suggests that via mechanisms which elevate HDL cholesterol and also release endogenous prostacyclin, niacin should be a potent agent in the long-term treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112221     DOI: 10.1016/0306-9877(90)90062-j

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience.

Authors:  M H Luria; D Sapoznikov
Journal:  Postgrad Med J       Date:  1993-04       Impact factor: 2.401

2.  Antiatherosclerotic Effects of 1-Methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor-Deficient Mice: A Comparison with Nicotinic Acid.

Authors:  Lukasz Mateuszuk; Agnieszka Jasztal; Edyta Maslak; Marlena Gasior-Glogowska; Malgorzata Baranska; Barbara Sitek; Renata Kostogrys; Agnieszka Zakrzewska; Agnieszka Kij; Maria Walczak; Stefan Chlopicki
Journal:  J Pharmacol Exp Ther       Date:  2015-12-02       Impact factor: 4.030

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.